中国药物警戒 ›› 2022, Vol. 19 ›› Issue (12): 1325-1331.
DOI: 10.19803/j.1672-8629.20210641

• 基础与临床研究 • 上一篇    下一篇

丹参川芎嗪注射液治疗冠心病合并高血压病联合用药的复杂网络分析

程序1,2, 张利丹1, 谢雁鸣1,*, 高阳1, 杨云云3   

  1. 1中国中医科学院中医临床基础医学研究所,北京 100700;
    2中国中医科学院广安门医院,北京 100053;
    3中国人民大学统计学院,北京 100872
  • 收稿日期:2021-06-07 出版日期:2022-12-15 发布日期:2022-12-21
  • 通讯作者: *谢雁鸣,女,首席研究员·博导,中医临床评价方法。E-mail:ktzu2018@163.com
  • 作者简介:程序,女,硕士,嗜酸性粒细胞与冠心病。
  • 基金资助:
    国家重点研发计划(2018YFC1707400); 中国中医科学院自主选题项目(20648)

Complex network analysis of combined medications of Danshen Ligustrazine injection in the treatment of coronary heart disease complicated with hypertension

CHENG Xu1,2, ZHANG Lidan1, XIE Yanming1,*, GAO Yang1, YANG Yunyun3   

  1. 1Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China;
    2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;
    3School of Statistics, Renmin University of China, Beijing 100872, China
  • Received:2021-06-07 Online:2022-12-15 Published:2022-12-21

摘要: 目的 通过分析真实世界中丹参川芎嗪注射液治疗冠心病合并高血压病的联合用药复杂网络,为临床优效方案的选择提供借鉴。方法 基于医院信息管理系统(HIS)电子医疗数据仓库,提取2006年10月1日至2015年12月30日全国12家三甲医院的1 930例应用丹参川芎嗪注射液的冠心病合并高血压病患者,采用Tabu搜索算法及复杂网络分析方法,对丹参川芎嗪注射液治疗冠心病合并高血压病相关证候的联合用药情况进行群组模块分析。结果 1 930例患者平均年龄(74.16±10.10)岁,男性多于女性,体力劳动者居多。入院病情一般者占比最多,其他合并症多为2型糖尿病、脑梗死等。给药途径均为静脉滴注,用法符合说明书;平均单次用药剂量为(12.85±4.46) mL,平均用药天数为(4.36±2.16) d。丹参川芎嗪注射液治疗冠心病合并高血压病分别优选联合单硝酸异山梨酯+尼卡地平/缬沙坦氨氯地平片、联合美托洛尔/肝素类/乙酰水杨酸、阿伐他汀/左卡尼汀等方案;对中医药联合用药可优选联合红花注射液+复方丹参滴丸+麝香保心丸/速效救心丸 、联合通心络胶囊、联合复方感冒灵颗粒/VC银翘片/银黄含片/复方黄连素片、联用四磨汤口服液/益气养阴剂等方案。结论 通过对临床治愈及好转人群核心联用药做子结构的划分,可以得到核心联用的西药和中药子群以及各子群子结构间的联系。为临床优效方案和路径构建提供线索,为进一步研究提供基础和研究方向。

关键词: 丹参川芎嗪, 注射液, 真实世界研究, 冠心病, 高血压病, 联合用药

Abstract: Objective To analyze the complex network of combined medications of Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection in the treatment of coronary heart disease complicated with hypertension in the real world so as to provide reference for the selection of clinically effective regimens. Methods From the large-scale electronic medical electronic data warehouse constructed by the Institute of Clinical Basic Medicine of Chinese Academy of Chinese Medical Sciences, the data of 1 930 patients with coronary heart disease and hypertension who had been treated with Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection between October 1, 2006 and December 30, 2015 was retrieved and analyzed based on the hospital information system(HIS). The Tabu search algorithm and complex network analysis method were used to conduct group module analysis. Results The average age of the 1 930 patients was (74.16±10.10) years old. Males patients outnumbered female ones. Most of them were manual laborers. Most of the inpatients were in mild condition. Other comorbidities were mostly type 2 diabetes and cerebral infarction. The route of administration was intravenous drips. The drugs were used in line with the instructions. The average single dose was (12.85±4.46) mL. The average duration of administration was (4.36±2.16) days. Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection were preferably combined with isosorbide mononitrate + nicardipine/valsartan and amlodipine tablets, metoprolol/heparins/acetylsalicylic acid, atorvastatin/levcarne Ting and other programs in the treatment of coronary heart disease complicated with hypertension. For traditional Chinese medicine, Salviae Miltiorrhizae and Ligustrazine Hydrochloride Injection were combined with Safflower Injection + compound Danshen dropping pills + Shexiang Baoxin pills/Suxiao Jiuxin pills, Tongxin luo capsules, compound Ganmaoling granules/VC Yinqiao tablets/Yinhuang Buccal tablets/compound Huangliansu tablets, the Simo decoction oral liquid/qi and yin nourishing agent. Conclusion By dividing the core combined drugs used by the clinically cured and improving populations into sub-structures, we can see more clearly the relationships between the sub-groups of the core combined medications with western and traditional Chinese medicine and between the sub-structures of each sub-group, which provide clues to the selection of clinically superior programs and pathways.

Key words: Ligustrazine hydrochloride, injection, real-world study, coronary heart disease, hypertension, combined medication

中图分类号: